Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Infinity Pharmaceuti (INFI)

Infinity Pharmaceuti (INFI)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 67,294
  • Shares Outstanding, K 57,029
  • Annual Sales, $ 22,150 K
  • Annual Income, $ -11,250 K
  • 60-Month Beta 1.87
  • Price/Sales 3.09
  • Price/Cash Flow N/A
  • Price/Book 3.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.21
  • Number of Estimates 3
  • High Estimate -0.19
  • Low Estimate -0.22
  • Prior Year -0.14
  • Growth Rate Est. (year over year) -50.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.90 +31.11%
on 11/13/19
1.31 -9.92%
on 12/05/19
+0.25 (+27.02%)
since 11/11/19
3-Month
0.82 +43.90%
on 11/07/19
1.31 -9.92%
on 12/05/19
-0.06 (-4.84%)
since 09/11/19
52-Week
0.82 +43.90%
on 11/07/19
1.95 -39.49%
on 03/14/19
-0.09 (-7.09%)
since 12/11/18

Most Recent Stories

More News
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.4900 (+0.23%)
BMY : 62.41 (+0.52%)
INFI : 1.18 (-1.67%)
RCUS : 8.81 (+3.04%)
Infinity (INFI) Q3 Loss Wider Than Expected, IPI-549 in Focus

Infinity's (INFI) wider-than-estimated loss in Q3 displeases investors. Revenues too fall short of the mark.

RHHBY : 38.4900 (+0.23%)
BMY : 62.41 (+0.52%)
INFI : 1.18 (-1.67%)
RCUS : 8.81 (+3.04%)
Infinity Pharmaceuticals (INFI) Reports Q3 Loss, Lags Revenue Estimates

Infinity (INFI) delivered earnings and revenue surprises of -11.11% and -59.65%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

INFI : 1.18 (-1.67%)
Infinity: 3Q Earnings Snapshot

CAMBRIDGE, Mass. (AP) _ Infinity Pharmaceuticals Inc. (INFI) on Wednesday reported a third-quarter loss of $11.4 million, after reporting a profit in the same period a year earlier.

INFI : 1.18 (-1.67%)
Infinity Pharmaceuticals Provides Company Update and Third Quarter 2019 Financial Results

-- MARIO-3 Enrollment Completion and Data Presentation Expected in 2020 --

INFI : 1.18 (-1.67%)
Breast Cancer Awareness Month Arrives With New Teamwork From Biotech Developers on the Way

USA News Group - As October rolled in to welcome the 35th annual Breast Cancer Awareness Month, hope remains alive as new drugs continue to develop from the biotech sector. These include the smaller cap...

PFE : 38.22 (-0.68%)
MRK : 88.98 (-0.13%)
RHHBY : 38.4900 (+0.23%)
INFI : 1.18 (-1.67%)
ONCY : 1.12 (+1.82%)
ONC.TO : 1.48 (+2.07%)
Infinity Announces the Date of Its Third Quarter 2019 Financial Results Conference Call and Webcast

Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) will host a conference call on Wednesday, October 30, 2019 at 4:30 p.m. ET to review its third quarter 2019 financial results and provide an update on the...

INFI : 1.18 (-1.67%)
Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

Verastem's (VSTM) Copiktra gets orphan drug designation from the FDA for use in the treatment of T-Cell lymphoma.

SNY : 49.01 (+1.91%)
MRK : 88.98 (-0.13%)
VSTM : 1.44 (+2.49%)
INFI : 1.18 (-1.67%)
Infinity's (INFI) IPI-549 in Focus in a Crowded Cancer Space

Infinity (INFI) is currently focusing on the development of its lead immuno-oncology candidate IPI-549, an orally administered treatment that selectively inhibits phosphoinositide-3 kinase (PI3K)-gamma....

BMY : 62.41 (+0.52%)
RHHBY : 38.4900 (+0.23%)
INFI : 1.18 (-1.67%)
RCUS : 8.81 (+3.04%)
Infinity Initiates 2 Studies for Lead Candidate IPI-549

Infinity (INFI) initiates two studies for IPI-549 -- a first-in-class, oral immuno-oncology product candidate.

BMY : 62.41 (+0.52%)
RHHBY : 38.4900 (+0.23%)
INFI : 1.18 (-1.67%)
RCUS : 8.81 (+3.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 32% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Trade INFI with:

Business Summary

Infinity Pharmaceuticals, Inc. is an innovative cancer drug discovery and development company that is seeking to leverage its strength in small molecule drug technologies to discover, develop, and deliver to patients best-in-class medicines for the treatment of cancer and related conditions.

See More

Key Turning Points

2nd Resistance Point 1.28
1st Resistance Point 1.23
Last Price 1.18
1st Support Level 1.15
2nd Support Level 1.12

See More

52-Week High 1.95
Fibonacci 61.8% 1.52
Fibonacci 50% 1.38
Fibonacci 38.2% 1.25
Last Price 1.18
52-Week Low 0.82

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar